Kuhn DJ - Search Results

1

Proteasome inhibitors in cancer therapy: lessons from the first decade.

Orlowski RZ, Kuhn DJ. Orlowski RZ, et al. Among authors: kuhn dj. Clin Cancer Res. 2008 Mar 15;14(6):1649-57. doi: 10.1158/1078-0432.CCR-07-2218. Clin Cancer Res. 2008. PMID: 18347166 Review.

2

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC. Chauhan D, et al. Clin Cancer Res. 2011 Aug 15;17(16):5311-21. doi: 10.1158/1078-0432.CCR-11-0476. Epub 2011 Jun 30. Clin Cancer Res. 2011. PMID: 21724551 Free PMC article.

3

Second generation proteasome inhibitors: carfilzomib and immunoproteasome-specific inhibitors (IPSIs).

Kuhn DJ, Orlowski RZ, Bjorklund CC. Kuhn DJ, et al. Curr Cancer Drug Targets. 2011 Mar;11(3):285-95. doi: 10.2174/156800911794519725. Curr Cancer Drug Targets. 2011. PMID: 21247387 Review.

4

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Kuhn DJ, Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ. Kuhn DJ, et al. Blood. 2009 May 7;113(19):4667-76. doi: 10.1182/blood-2008-07-171637. Epub 2008 Dec 2. Blood. 2009. PMID: 19050304 Free PMC article.

5

The immunoproteasome as a target in hematologic malignancies.

Kuhn DJ, Orlowski RZ. Kuhn DJ, et al. Semin Hematol. 2012 Jul;49(3):258-62. doi: 10.1053/j.seminhematol.2012.04.003. Semin Hematol. 2012. PMID: 22726549 Free PMC article. Review.

6

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.

Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, Orlowski RZ. Kuhn DJ, et al. Blood. 2007 Nov 1;110(9):3281-90. doi: 10.1182/blood-2007-01-065888. Epub 2007 Jun 25. Blood. 2007. PMID: 17591945 Free PMC article.

7

Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.

Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Voorhees PM, et al. Among authors: kuhn dj. Clin Cancer Res. 2007 Nov 1;13(21):6469-78. doi: 10.1158/1078-0432.CCR-07-1293. Clin Cancer Res. 2007. PMID: 17975159

8

Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.

Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D, Corral LG, Krenitsky VP, Xu W, Moutouh-de Parseval L, Webb DR, Mercurio F, Nakayama KI, Nakayama K, Orlowski RZ. Chen Q, et al. Among authors: kuhn dj. Blood. 2008 May 1;111(9):4690-9. doi: 10.1182/blood-2007-09-112904. Epub 2008 Feb 27. Blood. 2008. PMID: 18305219 Free PMC article.

9

Bortezomib and EGCG: no green tea for you?

Shah JJ, Kuhn DJ, Orlowski RZ. Shah JJ, et al. Among authors: kuhn dj. Blood. 2009 Jun 4;113(23):5695-6. doi: 10.1182/blood-2009-03-204776. Blood. 2009. PMID: 19498025 Free PMC article.

10

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Bjorklund CC, et al. Among authors: kuhn dj. J Biol Chem. 2011 Apr 1;286(13):11009-20. doi: 10.1074/jbc.M110.180208. Epub 2010 Dec 28. J Biol Chem. 2011. PMID: 21189262 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters